tbuckley/cabot-search huggingface dataset:
STEM-13. CANCER STEM CELL CYTOTOXICITY ASSAY-GUIDED TREATMENT IN RECURRENT GLIOBLASTOMA AND PROGRESSIVE ANAPLASTIC GLIOMA
Authors: Tulika Ranjan, Candace Howard, Alexander Yu, Linda Xu, Khaled Aziz, David Jho, Jodi Leonardo, Muhammad Hameed, Stephen Karlovits, Rodney Wegner, Russell Fuhrer, Seth Lirette, Krista Denning, Jagan Valluri, Pier Paolo Claudio
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The presence of chemotherapy-resistant cancer stem cells (CSC) leading to tumor recurrence is postulated to be one of the major factors in the poor response to the current standard of care treatments in progressive high-grade gliomas. Unfortunately, in spite of several new drug discoveries for other tumor types, not many advances have been reported for this disease and therefore recurrent and progressive high-grade glioma survival remains dismal. METHODS We have used a CLIA and CAP accredited Cancer Stem Cell Cytotoxicity Assay(ChemoID) to guide most effective chemotherapy treatments from a panel of FDA approved drugs or their combinations for 12 recurrent glioblastoma (GBM) patients and 2 progressive anaplastic gliomas, all eligible to receive a stereotactic biopsy. Patients were evaluated by MRI scans and response was assessed according to RANO criteria. RESULTS The median age of our patient cohort was 49 years (21–63), with 11 males (79%) and 3 females (21%). We observed 6 complete responses (CR) 43%, 6 partial responses (PR) 43%, and 2 progressive diseases (PD) 14%. Of note, the two PD were observed in patients that could not be treated with assay recommended therapy due to their health status. Patients treated with ChemoID assay-directed therapy had a longer median overall survival (OS) of 13.3 months (5.4-NA) compared to the historical median OS of 9.0 months (8.0–10.8 months) previously reported (1). Notably, our recurrent and progressive high-grade glioma patient cohort treated with assay-guided therapy had a 57% probability to survive at 12 months, compared to the 27% historical probability of survival at 12 months observed in previous studies (1). CONCLUSIONS The data suggests that the ChemoID Cancer Stem Cell Cytotoxicity Assay has the potential to help guide individualized chemotherapy choices to improve recurrent and progressive high-grade glioma patient outcome. 1) Friedman, H.S. et. al. JCO2009 27:28, 4733–4740.
Cytoreductive nephrectomy for metastatic renal cell carcinoma in the presence of nonconventional histology
Authors: W. Kassouf, R. Sanchez-Ortiz, P. Tamboli, S. Matin, D. Swanson
Journal: Journal of Clinical Oncology (2006)

14535 Background: While randomized trials show a survival benefit for cytoreductive nephrectomy in the setting of metastatic conventional (clear cell) renal cell carcinoma (mRCC), the benefit of cytoreductive surgery for patients with mRCC of nonconventional histology (papillary, chromophobe, unclassified) is unknown. We evaluated our experience with cytoreductive nephrectomy for nonconventional mRCC at M. D. Anderson. Methods: From 1990–2004, 464 patients with mRCC underwent cytoreductive nephrectomy; of these, 89 patients had nonconventional mRCC and form the basis of this report. The remaining 375 patients with conventional mRCC formed a comparative group. Overall survival (OS) and disease-specific survival (DSS) data were evaluated by Kaplan and Meier analysis, with univariate and multivariate log rank tests. Results: Compared to patients with conventional histology, patients with nonconventional mRCC were younger (p &lt; 0.045), more likely to have nodal metastases (p &lt; 0.0001), and more likely to have sarcomatoid dedifferentiation (21.2 versus 13.2%, p = 0.056). In multivariate analysis, the median survival for nonconventional histology was significantly worse than for conventional mRCC (11.1 versus 19.5 months, p = 0.0081), even after adjusting for stage, grade, performance status, age, and presence of sarcomatoid dedifferentiation. Although positive nodal status was associated with a decreased survival in nonconventional histology (p &lt; 0.0001) in our multivariate analysis, even node negative patients demonstrated a worse survival when compared to those with conventional histology (p = 0.03). Interestingly, patients with nonconventional mRCC who had complete resection of their retroperitoneal nodal metastases with cytoreduction showed a trend towards improved survival, as has been reported in patients with conventional mRCC and nodal disease. Conclusions: Patients with nonconventional mRCC have a higher incidence of nodal metastases and demonstrate a worse prognosis than those with conventional histology, who undergo cytoreductive surgery. Aggressive cytoreduction with removal of all nodal disease may improve outcomes. More effective systemic therapies are needed to improve upon the results seen with aggressive surgery. No significant financial relationships to disclose.
Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Authors: Bachar Samra, Hagop M. Kantarjian, Koji Sasaki, Marina Y Konopleva, Rita Khouri, Susan M. O'Brien, Alessandra Ferrajoli, Cesar Nunez, Tapan M. Kadia, Elias Jabbour
Journal: Blood (2019)
Acceleration of AML Progression By Cigarette Smoke Exposure or Condensate Exposure and Associated DNA Methylation Alterations
Authors: Mary Figueroa, Mansour Alfayez, Yue Lu, Marcos Estecio, Seyed Javad Moghaddam, Marina Y Konopleva, Elias Jabbour, Courtney D. DiNardo, Joya Chandra
Journal: Blood (2019)
Approximating International Myeloma Working Group Uniform Response Criteria to Derive Response for Multiple Myeloma (MM) Patients Using Data from Electronic Health Records (EHR)
Authors: Rebekah B. Foster, Max Tromanhauser, Christopher Gayer, Patrick K. Gonzales, Kathleen Maignan, Adomah S. Opong, Aracelis Z. Torres, Kenneth R. Carson
Journal: Blood (2019)
Niacin protects against abdominal aortic aneurysm formation via GPR109A independent mechanisms: role of NAD+/nicotinamide
Authors: Tetsuo Horimatsu, Andra L Blomkalns, Mourad Ogbi, Mary Moses, David Kim, Sagar Patel, Nicole Gilreath, Lauren Reid, Tyler W Benson, Jonathan Pye, Samah Ahmadieh, Allie Thompson, Nathan Robbins, Adrien Mann, Ashlee Edgell, Stephanie Benjamin, Brian K Stansfield, Yuqing Huo, David J Fulton, Gautam Agarwal, Nagendra Singh, Stefan Offermanns, Neal L Weintraub, Ha Won Kim
Journal: Cardiovascular Research (2019)

Chronic adventitial and medial infiltration of immune cells play an important role in the pathogenesis of abdominal aortic aneurysms (AAAs). Nicotinic acid (niacin) was shown to inhibit atherosclerosis by activating the anti-inflammatory G protein-coupled receptor GPR109A [also known as hydroxycarboxylic acid receptor 2 (HCA2)] expressed on immune cells, blunting immune activation and adventitial inflammatory cell infiltration. Here, we investigated the role of niacin and GPR109A in regulating AAA formation.
CD244 Marks Non-Functional Hematopoietic Stem Cells with a Mast Cell Signature after Induction of Endoplasmic Reticulum Stress
Authors: Valgardur Sigurdsson, Shuhei Koide, Visnja Radulovic, Els Mansell, Mark Van Der Garde, Tiit Örd, Tonis Örd, Kenichi Miharada
Journal: Blood (2019)
Effect of Depression on Health Related Quality of Life and Adherence and Its Correlation with Response Rates in Patients of Chronic Myeloid Leukemia on First Line Imatinib and Nilotinib - a Prospective, Institutional Analysis of Real World Data from India
Authors: Pratibha Bhatia, Sumeet Prakash Mirgh, Vishvdeep Khushoo, Faran Naim, Ambar Garg, Rayaz Ahmed, Narendra Agrawal, Dinesh Bhurani
Journal: Blood (2019)
QOLP-10. PATIENT-REPORTED OUTCOMES DURING TREATMENT FOR GLIOBLASTOMA: SYMPTOM BURDEN AND ASSOCIATED IMPACT ON DAILY LIFE
Authors: Meghan Hultman, Megan Tipps, Minda Liu, Nilanjana Banerji, Patricia Bruns, John Trusheim
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Glioblastoma is the most common primary malignant brain tumor, with an annual incidence of 3–4 new cases per 100,000 people. Despite advances in chemotherapy, radiotherapy, and surgical interventions, prognosis remains poor. Aims of treatment for life-limiting diagnoses should extend beyond increasing survival time to include palliation of symptoms and promotion of quality of life. Here we describe patient-reported symptoms both early and late in the glioblastoma treatment trajectory, as well as their associated interference with daily life. METHODS Fifty patients with newly diagnosed glioblastoma were recruited between September 2015-March 2018. Demographic and clinical information was collected from medical records. Patients also completed the brain tumor-specific MD Anderson Symptom Inventory (MDASI-BT) approximately every 8 weeks from completion of chemoradiation through cessation of active disease treatment. Both individual and categories of related symptoms reported in the initial two (early treatment) and final two (late treatment) MDASI-BT assessments were examined for symptom frequency, severity, and relationships between symptom severity and interference with daily life. Patients still receiving treatment or who completed &lt; 4 total MDASI-BT assessments were excluded from the analysis. RESULTS The most commonly reported symptoms were often, but not always, consistent with the symptoms rated as most severe. This was true for individual symptoms as well as categories of symptoms. The most common/severe symptoms also changed from early to late treatment. Overall symptom burden was positively correlated with symptom interference in daily life (r=0.67, p&lt; 0.0001). Regression analysis identified different symptoms as predictors of interference in early as opposed to late treatment, and these predictors did not necessarily align with the most common/severe symptoms. CONCLUSION Symptom experience for patients with glioblastoma is complex and dynamic. Attention to symptom trajectories for patients with glioblastoma may direct approaches to assessment, early identification, and symptom management, thus promoting better quality of life.
TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins
Authors: Ashwin Kishtagari, Yihong Guan, Cassandra M Kerr, Hassan Awada, Jibran Durrani, Edward F Greenberg, Xiaorong Gu, Feng Pan, Valeria Visconte, Dewen You, Guangbo Qu, Amy C Graham, Bartlomiej P. Przychodzen, Thomas Laframboise, Hideki Makishima, Daniel Gackowski, Ryszard Ólinski, Yu-Wei Cheng, Mikkael A. Sekeres, Mingjiang Xu, Babal K. Jha, Jaroslaw P. Maciejewski
Journal: Blood (2019)
Hematopoietic Stem Cell Transplantation in Βthalassemia Major: The Egyptian Outcome
Authors: Amal El-Beshlawy, Amina AbdelSalam, Gamal Fathy, Khaled M. Salamaa, Mona El ghamrawy, Samar S. Ramadan, Alaa M. Elhaddad
Journal: Blood (2019)
Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias
Authors: Daichi Inoue, Chew Guo-Liang, Bo Liu, Stanley C Lee, Brittany C Michel, Joey Pangallo, Andrew R D'Avino, Khrystyna North, Lillian E Bitner, Muran Xiao, Susumu Kobayashi, Akihide Yoshimi, Hana Cho, Sydney X Lu, Justin Taylor, Cigall Kadoch, Robert K. Bradley, Omar Abdel-Wahab
Journal: Blood (2019)
Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma
Authors: Tessa Han, Stephane Minvielle, Anil Aktas Samur, Mariateresa Fulciniti, Florence Magrangeas, Paul G. Richardson, Philippe Moreau, Michel Attal, Kenneth C. Anderson, Hervé Avet-Loiseau, Giovanni Parmigiani, Mehmet Kemal Samur, Nikhil C. Munshi
Journal: Blood (2019)
Ibrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in Community Clinical Practice Outside of Clinical Trials
Authors: Vladimir I. Vorobyev, Vera A. Zherebtsova, Egor I. Dubrovin, Liudmila A. Bychenkova, Lev S. Butaev, Larisa A. Muha, Yulia B. Kochkareva, Valentina L. Ivanova, Eugene A. Nikitin, Gayane Tumyan, Vadim A Doronin, Oleg I. Krijanovski, Vadim Ptushkin
Journal: Blood (2019)
Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice
Authors: Stuart L. Goldberg, Michael J. Mauro, Jorge E. Cortes, Scott Justin Keating, Hitesh Bhandari, Clara Chen
Journal: Blood (2019)
INNV-07. THE KOREAN SOCIETY FOR NEURO-ONCOLOGY (KSNO) GUIDELINE FOR GLIOMAS: VERSION 2019.01
Authors: Young Zoon Kim, Chae-Yong Kim, Do Hoon Lim, Dong-Sup Chung
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND There was no practical guideline for the management of patients with central nervous system (CNS) tumor in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, started to prepare a guideline for CNS tumors from February 2018. METHODS The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified through searches of PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL using specific and sensitive keywords as well as combinations of keywords. RESULTS First, for the glioblastoma as WHO Grade IV Gliomas, the maximal safe resection if feasible is recommended. Patients aged ≤ 70 years with good performance should be treated by concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide chemotherapy (Stupp’s protocol) or standard brain radiotherapy alone. However, those with poor performance should be treated by hypofractionated brain radiotherapy (preferred) ± concurrent or adjuvant temozolomide or temozolomide alone (Level III) or supportive treatment. Second, for the WHO Grade III Gliomas, patients with anaplastic astrocytoma, IDH-mutant should be treated by standard brain radiotherapy followed by adjuvant temozolomide chemotherapy, or Stupp’s protocol, or standard brain radiotherapy with neoadjuvant or adjuvant PCV chemotherapy, or Standard brain radiotherapy alone (Level III). However, those anaplastic astrocytoma, IDH-wildtype should be treated by the protocol for glioblastoma. Third, for the WHO Grade II Gliomas, patients with diffuse astrocytoma, IDH-wildtype without molecular feature of glioblastoma should be treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy (Level III), or standard brain radiotherapy alone, or observation. And patients with diffuse astrocytoma IDH-mutant and oligodendroglioma (IDH-mutant and 1p/19q codeletion) should be treated according to the risk factors. CONCLUSION The recent KSNO’s guideline recommends that glioma should be treated according to the molecular as well as histological features. However, the practice can be limited by the National Insurance for Health in Korea.
Volvulus of Small Intestine
Authors: T. A. Ouilliam
Journal: BMJ (1946)

~~~~~~~~~~~~~~~~~~~~~~-MEDICAI.JOURNAL brane had been sloughed, but section proved this was not the case.On May 20 immobility of the palate was noticed.On May 22 he had attacks of vomiting, the pulse rate was very slow, and there were occasional extrasystoles.These attacks continued until May 24, when the pulse rate was about 30 and the blood pressure 85/6tU.The patient died on May 24-a typical case of early cardiac failure.' most unusual, unexpected, and rapid disappearance of the extent of gelatinous membrane," that penicillin saved his case of bull-neck diphtheria.His description corresponds fairly well with our first case.
The Prognosis of PR Patients after Induction Therapy Was Not Inferior to CR in ASCT-Eligible NDMM Patient.
Authors: Anna Takahashi, Yuko Mishima, Norihito Inoue, Yoshiharu Kusano, Hirofumi Yamauchi, Kyoko Ueda, Noriko Nishimura, Masahiro Yokoyama, Yasuhito Terui, Kiyohiko Hatake
Journal: Blood (2016)
BEAM Vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society
Authors: Riccardo Saccardi, Manuela Badoglio, Joachim Burman, Grzegorz Helbig, Majid A. Kazmi, Giovanni Mancardi, Stephan Mielke, John Moore, Paolo Muraro, Jaime Sanz, Basil Sharrack, Marek Smilowski, Maria Pia Sormani, John A Snowden
Journal: Blood (2019)
PDCT-10. FEASIBILITY OF LEUKAPHERESIS FOR HARVESTING MONOCYTES AND GENERATING AUTOLOGOUS DENDRITIC CELL VACCINES IN CHILDREN WITH MALIGNANT BRAIN TUMORS
Authors: Daniel Landi, Gary Archer, Timothy Driscoll, James Herndon, John Sampson, David Ashley
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Recurrent medulloblastoma and malignant glioma are virtually incurable. In children, these tumors are often disseminated or occur in deep midline structures that preclude surgery and are not amenable to highly inflammatory treatments. Active immunization is an attractive immunotherapeutic approach. We are conducting a phase I trial evaluating autologous CMV pp65 RNA-pulsed dendritic cell (DC) vaccines in children with recurrent malignant glioma or medulloblastoma. A primary objective is establishing the feasibility of using leukapheresis to harvest sufficient monocytes in order to generate at least 3 autologous DC vaccines. METHODS For children unable to receive two 16-guage IVs, a temporary pheresis catheter is placed in the jugular vein under anesthesia. Leukapheresis is performed with the goal of processing 3 total blood volumes. Circulating monocytes are collected and cultured for 7 days in media supplemented with GM-CSF and IL-4, then matured into dendritic cells and loaded with antigen. The target dose for a single vaccine is 2 x 107 dendritic cells. RESULTS To date, five patients (ages 9, 13, 16, 17, 30) have undergone leukapheresis. All patients tolerated leukapheresis without complications, with run times between 3 to 6 hours depending on achievable pheresis flow rate. Patients generated 2, 3, 7, 8, 8, and 8 vaccines. The medulloblastoma patient who generated 2 vaccines underwent a second leukapheresis that generated 8 vaccines. In this patient, although the initial leukapheresis collected a high number of monocytes, the conversion rate to mature DCs was low. Thusfar, there has not been a strong correlation between the number of monocytes collected and the eventual number of mature dendritic cells. CONCLUSIONS Leukapheresis is tolerable for younger children and appears to be a viable strategy for harvesting sufficient monocytes for creating DC vaccines. Conversion rates between harvested monocytes and the final number of mature dendritic cells vary.
RARE-16. A NOVEL RADIOMICS MODEL DIFFERENTIATING CHORDOMA AND CHONDROSARCOMA
Authors: Erika Yamazawa, Satoshi Takahashi, Shota Tanaka, Wataru Takahashi, Takahiro Nakamoto, Shunsaku Takayanagi, Yosuke Kitagawa, Taijun Hana, Tsukasa Koike, Yoshihiro Kushihara, Masahiro Shin, Nobuhito Saito
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Chordoma and chondrosarcoma account for the majority of skull base tumors affecting the petroclival region. Chondrosarcoma has better prognosis than chordoma; heavy particle therapy is often indicated for residual/recurrent chordoma. Preoperative, precise diagnosis of the tumor would be desirable, as it can potentially impact on the choice of a surgical approach and the aggressiveness of surgery. METHODS We conducted a radiomics study to create a machine learning model distinguishing chondrosarcoma from chordoma. We collected DICOM T2-weighted images and T1-weighted images with gadolinium (GdT1) enhancement in the consective patients of chordoma or chondrosarcoma who underwent surgery at The University of Tokyo Hospital from September of 2012 to January of 2019. We selected patients with uniform MRI images. VOI (volume of interest) was set using Monaco (https://www.elekta.com/software-solutions/treatment-management/external-beam-planning/monaco.html). Not only sematic features but also agnostic features were calculated. The original images and 8 wavelet transformed images were calculated for texture agnostic features such as Gray-Level Co-occurrence Matrix (GLCM). Features were selected by recursive feature elimination (RFE). The final model evaluation was performed by average area under the curve (AUC). RESULTS The study population included 17 chordomas and 22 chondrosarcomas in a total of 39 patients. 476 features were obtained per image sequence. The number of features per case was 476 × 2 = 952 The most accurate machine learning model was created using the extracted three features from only T2. The best AUC was 0.77 ± 0.11 in logistic regression (dataset was divided randomly into halves, average value of AUC calculated six times). CONCLUSIONS This novel machine learning model can differentiate chordoma and chondrosarcoma reasonably well. A validation study with a larger number of patients is warranted.
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies
Authors: Andrea Necchi, Daniele Raggi, Andrea Gallina, Russell Madison, Maurizio Colecchia, Roberta Lucianò, Rodolfo Montironi, Patrizia Giannatempo, Elena Farè, Filippo Pederzoli, Marco Bandini, Marco Bianchi, Renzo Colombo, Giorgio Gandaglia, Nicola Fossati, Laura Marandino, Umberto Capitanio, Federico Dehò, Siraj M. Ali, Jon H. Chung, Jeffrey S. Ross, Andrea Salonia, Alberto Briganti, Francesco Montorsi
Journal: European Urology (2019)
IMMU-51. PROFILING THE IMMUNE SYSTEM IN PRIMARY AND RECURRENT GLIOBLASTOMA
Authors: Kelsey Maddison, Moira Graves, Nikola Bowden, Ricardo Vilain, Michael Fay, Paul Tooney
Journal: Neuro-Oncology (2019)

Abstract Immunotherapy has been shown to have benefit in some solid tumours including melanoma where immune infiltration can be pronounced. Until recently the central nervous system was thought to be immune privileged. Whilst research has shown that immune cells are capable of infiltrating tumours from glioblastoma patients, to date immunotherapy trials have not consistently shown a benefit in these patients. The aim of this study was to profile the immune system in primary and recurrent tumours from glioblastoma patients. Formalin-fixed paraffin-embedded sections of primary and matched recurrent tumours from 13 patients with glioblastoma were processed for immunohistochemical labelling of a range of immune cell markers. Immune infiltration was scored on digitally scanned immunolabelled sections using a categorical system of 0 (absent), 1 (present), 2 (moderate) and 3 (marked). CD3+ cells were observed in three topographical locations within primary and recurrent glioblastoma tumours namely the tumour proper, perivascular spaces and associated with haemorrhages within the tumour. CD3+ cell infiltration into the tumour proper was present (Score = 1) in 7 of 13 primary and recurrent tumours. Only one case (case #9) had CD3+ infiltration scores &gt; 1 for both primary (score = 3) and recurrent tumour (score = 2). CD3+ cells were observed in perivascular spaces in 10 of the 13 cases of primary and recurrent glioblastoma. Only case #9 had CD3+ cells in perivascular spaces that was scored &gt;1 for both primary and recurrent tumours. In conclusion, whilst CD3+ infiltration was observed in the tumour proper and perivascular spaces within both primary and recurrent glioblastomas, the level of infiltration was quite low in this small cohort and as such requires further investigation in a larger cohort.